RELATIONSHIP BETWEEN MELATONIN-FORMING FUNCTION OF EPIPHYSIS WITH HYPERURICEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE 5 STAGES

Petrova A., Karpenko O., Оstashevska T., Krasiuk E., Hryhorieva Y

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Aim. To analyze the prevalence of hyperuricemia in patients with stage 5 CKD treated with hemodialysis (HD) and to determine the relationship of pineal dysfunction with impaired purine metabolism. Object and methods. 130 people (50% of men) aged 58.5 were surveyed [43; 66] years on permanent hemodialysis treatment. Controls were 20 healthy individuals. The determination of daytime and nighttime levels of melatonin (MT) in saliva, based on the level of which, a group of patients with impaired MFE was isolated. Clinical and laboratory studies were carried out for all patients: general and biochemical blood tests with determination of uric acid level, office blood pressure (BP) measurements were performed. Results. Significant prevalence of MFE disorders in patients with stage 5 CKD treated with hemodialysis and its relationship to hyperuricemia has been identified. Analysis of uric acid (UC) levels between hemodialysis patients with stage 5 CKD and practically healthy subjects showed a higher value of 29.2% for patients with renal replacement therapy (NRT) (p <0.001). Conclusion. For patients with stage 5 CKD undergoing hemodialysis, there is a frequent violation of MFE (84.6%) and significant disorders of purine metabolism (74.6%). The analysis of the result of the study of purine metabolism showed more profound disorders in patients with impaired MFE, which may indicate a link between epiphysis dysfunction and hyperuricemia in patients with NRT. In patients with hemodialysis, disorders of purine metabolism are age-dependent and are determined by the duration of NRT, the experience of hypertension, hemoglobin levels, and MT levels. We have identified a relationship between impaired purine metabolism and MTF disturbance by daytime and nighttime MT.

chronic kidney disease, hemodialysis, melatonin, melatonin-forming function of the epiphysis, hyperuricemia, uric acid.

1. Syniachenko OV, Ihnatenko HA, Mukhin IV. Kliniko-laboratorni aspekty purynovoho obminu: norma ta patolohiia. Medytsyna zaliznychnoho transportu Ukrainy. 2004;1:96-100. [in Ukrainian].
2. Kapustianska AA. Rannia diahnostyka podahrychnoho artrytu na etapi pervynnoi medyko-sanitarnoi dopomohy. Svit medytsyny ta biolohii. 2013;4:104. [in Ukrainian].
3. Bellomo G. The relationship between uric acid, allopurinol, cardiovascular events, and kidney disease progression: a step forward. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015;65:525-7. DOI: 10.1053/j.ajkd.2015.01.001
4. Ichida K, Matsuo H, Takada T, Nakayama A, Keizo Murakami, Shimizu T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 2012;3. DOI: 10.1038/ncomms1756
5. Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, Sung S, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019. Available from: https://doi.org/10.1038/s41598-019-43241-3
6. Tareevoj IE. Nefrologija. Medicina; 2000. s. 46-7. [in Russian].
7. Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: An adjunct anti-hypertensive agent. Clin Exp Pharmacol Physiol. 2018 Aug;45(8):755-66. DOI: 10.1111/1440-1681.12942
8. Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2018;71:362-70. DOI: 10.1053/j.ajkd.2017.08.017
9. Nabavi SM, Nabavi SF, Sureda A, Xiao J, Dehpour AR, Shirooie S, et al. Anti-inflammatory effects of melatonin: a mechanistic review. Crit Rev Food Sci Nutr. 2019;59(1):4-16. DOI: 10.1080/10408398.2018.1487927
10.  Cuzzocrea S, Russel J Reiter. Pharmacological Actions of Melatonin in Acute and Chronic Inflammation. Current Topics in Medicinal Chemistry. 2002;2(2). DOI: 10.2174/1568026023394425
11. Anisimov VN, Popovich IG, Zabezhinski MA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. 2006;1757:573- 89.
12. Russcher M, Koch B, Nagtegaal E, van der Putten K, ter Wee P, Gaillard C. The role of melatonin treatment in chronic kidney disease. Front. Biosci. (Landmark Ed). 2012;17:2644-56.
13. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;39(33):3021-104. Available from: https://doi.org/10.1093/eurheartj/ehy339
14. Ramirez MEG, Bargma JM. Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy. Journal of Advanced Research. 2017;8:551-4. Available from: https://doi.org/10.1016/j.jare.2017.04.006
15. Kondratiuk VE, Petrova AS, Karpenko OV. Kharakterystyka melatoninutvoriuvalnoi funktsii epifiza u patsiientiv z khronichnoiu khvoroboiu nyrok u terminalnii stadii. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2019;4:94-102. DOI: http://dx.doi.org/10.30978/CEES-2019- 4-94 [in Ukrainian].
16. Hodzhakuliev BG, Begencheva GO, Ahmedova DM, Muhammedov MB, Kulyeva JeS. Klinicheskoe znachenie giperurikemii i obmena mochevoj kisloty v patologii serdechno-sosudistoj sistemy. Molodoj uchenyj. 2014;18:178-84. Dostupno: https://moluch.ru/archive/77/13123 [in Russian].
17. Raja S, Kumar A, Aahooja RD, Thakuria U, Ochani S, Shaukat F. Frequency of Hyperuricemia and its Risk Factors in the Adult Population. Cureus. 2019;11(3). DOI: 10.7759/cureus.4198
18. Ruilope LM, Garcia-Puig J. Hyperuricemia and Renal Function. Current Hypertension Reports. 2001;3:197-202.

«Bulletin of problems biology and medicine» Issue 1 (155), 2020 year, 183-187 pages, index UDK 616.61–008.6–036.11–053.2-037

10.29254/2077-4214-2020-1-155-183-187